

## Best of ASCO® 2023 in Japan

a program licensed by the American Society of Clinical Oncology, Inc.

## プログラム

※本セミナーでとりあげる演題は、2023年6月2日～6月6日に開催された米国臨床腫瘍学会（ASCO）の年次総会の演題の中から重要なものをASCOのプログラム委員会が指定し、日本臨床腫瘍学会のBest of ASCO部会が選定したものです。但し、IDに \* 印のある演題は日本臨床腫瘍学会のBest of ASCO部会が独自で選定したものです。

| 7月8日（土曜日） |       | 演題数    | 講師   | 司会                            | コメンテーター                      |
|-----------|-------|--------|--|-------------------------------|------------------------------|
| 9:00      | 9:10  | 10 min | <b>Welcome &amp; Introduction</b>  |                               |                              |
| 9:10      | 9:30  | 20 min | <b>岩田 広治</b><br>愛知県がんセンター  | <b>能澤 一樹</b><br>愛知県がんセンター     | <b>下村 昭彦</b><br>国立国際医療研究センター |
| 9:30      | 9:45  | 15 min | <b>乳がん - Local/Regional/Adjuvant</b><br>Q&A  |                               |                              |
|           |       |        | <b>Abstract ID LBA500 / Dennis J. Slamon MD, PhD</b><br>Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.   |                               |                              |
|           |       |        | <b>Abstract ID 523* / Tadahiko Shien MD, PhD</b><br>A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017.   |                               |                              |
| 9:45      | 10:05 | 20 min | <b>乳がん - Metastatic</b>  |                               |                              |
| 10:05     | 10:20 | 15 min | <b>Q&amp;A</b>   |                               |                              |
|           |       |        | <b>下井 辰徳</b><br>国立がん研究センター中央病院   | <b>尾崎 由記範</b><br>がん研究会有明病院    |                              |
|           |       |        | <b>Abstract ID LBA1000 / Gabe S. Sonke MD, PhD</b><br>Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).  |                               |                              |
|           |       |        | <b>Abstract ID LBA1068* / Takahiro Kogawa MD, PhD</b><br>Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.   |                               |                              |
| 10:20     | 10:40 | 20 min | <b>Melanoma</b>  |                               |                              |
| 10:40     | 10:55 | 15 min | <b>Q&amp;A</b>   |                               |                              |
|           |       |        | <b>野村 基雄</b><br>京都大学医学部附属病院  | <b>小野澤 祐輔</b><br>静岡県立静岡がんセンター |                              |
|           |       |        | <b>Abstract ID LBA9503 / Muhammad Adnan Khattak, PhD, FRACP, MBBS</b><br>Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.   |                               |                              |
|           |       |        | <b>Abstract ID 101 / Irene L.M. Reijers MD</b><br>The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.   |                               |                              |
| 10:55     | 11:00 | 5 min  | Break  |                               |                              |
| 11:00     | 11:40 | 40 min | <b>オンコロジーライブセミナー① 日本イーライリリー株式会社</b><br>進行期乳癌を考える～局所療法から薬物療法まで～   |                               |                              |
|           |       |        | 【座長】三好 康雄（兵庫医科大学）<br>【演者】尾崎 由記範（がん研究会有明病院）<br>【演者】枝園 忠彦（岡山大学病院）  |                               |                              |
| 11:40     | 12:05 | 25 min | Break  |                               |                              |
| 12:05     | 12:25 | 20 min | <b>Developmental Therapeutics</b>  |                               |                              |
| 12:25     | 12:40 | 15 min | <b>Q&amp;A</b>   |                               |                              |
|           |       |        | <b>清水 俊雄</b><br>和歌山県立医科大学  | <b>衣斐 寛倫</b><br>愛知県がんセンター     | <b>石川 大</b><br>順天堂大学         |
|           |       |        | <b>Abstract ID 2510 / Yinghong Wang</b><br>First-line treatment of fecal microbiota transplantation for immune-mediated colitis.   |                               |                              |
|           |       |        | <b>Abstract ID LBA3000 / Funda Meric-Bernstam MD</b><br>Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.   |                               |                              |
| 12:40     | 13:10 | 30 min | <b>婦人科がん</b>   |                               |                              |
| 13:10     | 13:25 | 15 min | <b>Q&amp;A</b>   |                               |                              |
|           |       |        | <b>西川 忠晴</b><br>国立がん研究センター中央病院   | <b>松本 光史</b><br>兵庫県立がんセンター    |                              |
|           |       |        | <b>Abstract ID 5503 / Matthew A. Powell MD</b><br>Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC):Outcomes by blinded independent central review (BICR) of the RUBY trial(ENGOT-EN6-NSGO/GOG-3031/RUBY).   |                               |                              |
|           |       |        | <b>Abstract ID LBA5506* / Philipp Harter, MD, PhD</b><br>Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation(non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase IIIDUO-O trial. |                               |                              |
|           |       |        | <b>Abstract ID LBA5507* / Kathleen N. Moore, MD, MS</b><br>Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.                         |                               |                              |
| 13:25     | 13:45 | 20 min | <b>消化器がん - Gastrointestinal</b>  |                               |                              |
| 13:45     | 14:00 | 15 min | <b>Q&amp;A</b>   |                               |                              |
|           |       |        | <b>砂川 優</b><br>聖マリアンナ医科大学  | <b>門脇 重憲</b><br>愛知県がんセンター     |                              |
|           |       |        | <b>Abstract ID LBA2 / Deborah Schrag MD, FASCO, MPH</b><br>PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).  |                               |                              |
|           |       |        | <b>Abstract ID 3508 / Kentaro Yamazaki MD</b><br>Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.   |                               |                              |
| 14:00     | 14:05 | 5 min  | Break  |                               |                              |
| 14:05     | 14:45 | 40 min | <b>オンコロジーライブセミナー② 小野薬品工業株式会社</b><br>EvidenceとNarrativeの融合～BRAF変異陽性大腸癌の個別化治療とがん悪液質治療～   |                               |                              |
|           |       |        | 【座長】小松 嘉人（北海道大学病院）<br>【演者】室 圭（愛知県がんセンター）   |                               |                              |
| 14:45     | 14:50 | 5 min  | Break  |                               |                              |
| 14:50     | 15:05 | 15 min | <b>Central Nervous System Tumors</b>   |                               |                              |
| 15:05     | 15:15 | 10 min | <b>Q&amp;A</b>   |                               |                              |
|           |       |        | <b>荒川 芳輝</b><br>京都大学医学部附属病院  | <b>百田 洋之</b><br>国立長寿医療研究センター  |                              |
|           |       |        | <b>Abstract ID LBA1 / Ingo K. Mellinghoff, MD,FACP</b><br>INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2glioma with an IDH1/2 mutation.  |                               |                              |
| 15:15     | 15:35 | 20 min | <b>肺がん - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers</b>   |                               |                              |
| 15:35     | 15:50 | 15 min | <b>Q&amp;A</b>   |                               |                              |
|           |       |        | <b>大熊 裕介</b><br>国立がん研究センター中央病院   | <b>村上 晴泰</b><br>静岡県立静岡がんセンター  | <b>赤松 弘朗</b><br>和歌山県立医科大学    |
|           |       |        | <b>後藤 倭</b><br>国立がん研究センター中央病院  |                               |                              |
|           |       |        | <b>Abstract ID LBA3 / Roy S. Herbst, MD, PhD</b><br>Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIa non-small cell lung cancer (NSCLC).   |                               |                              |
|           |       |        | <b>Abstract ID LBA100 / Heather A. Wakelee MD, FASCO</b><br>KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.  |                               |                              |
| 15:50     | 16:10 | 20 min | <b>肺がん - Non-Small Cell Metastatic</b>   |                               |                              |
| 16:10     | 16:25 | 15 min | <b>Q&amp;A</b>   |                               |                              |
|           |       |        | <b>谷崎 潤子</b><br>近畿大学   | <b>村上 晴泰</b><br>静岡県立静岡がんセンター  | <b>赤松 弘朗</b><br>和歌山県立医科大学    |
|           |       |        | <b>後藤 倭</b><br>国立がん研究センター中央病院  |                               |                              |
|           |       |        | <b>Abstract ID 9004 / Yasushi Goto, MD</b><br>TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).   |                               |                              |
|           |       |        | <b>Abstract ID 9006 / Hiroaki Akamatsu MD, PhD</b><br>The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in advanced non-squamous, non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L).  |                               |                              |
| 16:25     | 16:30 | 5 min  | Break  |                               |                              |
| 16:30     | 17:10 | 40 min | <b>オンコロジーライブセミナー③ 第一三共株式会社</b><br>転移再発乳がんにおける抗HER2療法の動向とエンハーツの役割   |                               |                              |
|           |       |        | 【座長】能澤 一樹（愛知県がんセンター）<br>【演者】大西 舞（国立がん研究センター中央病院）   |                               |                              |
| 17:10     | 17:20 | 10 min | <b>Highlight of the day</b>  |                               |                              |
|           |       |        | <b>岩田 広治</b><br>愛知県がんセンター  |                               |                              |

# Best of ASCO® 2023 in Japan

a program licensed by the American Society of Clinical Oncology, Inc.

## プログラム

| 7月9日（日曜日）     | 演題数    | 講師   | 司会                     | コメンテーター                 |
|---------------|--------|--|------------------------|-------------------------|
| 9:00 – 9:40   | 40 min | 【座長】 泉 浩二（金沢大学）<br>【演者】 塩田 真己（九州大学）  |                        |                         |
| 9:00 – 9:40   | 40 min | オンコロジーライブセミナー④ ヤンセンファーマ株式会社・日本新薬株式会社 共催<br>転移性前立腺癌治療とその選択 – ASCO 2023 –  |                        |                         |
| 9:40 – 9:45   | 5 min  | Break  |                        |                         |
| 9:45 – 10:05  | 20 min | 福島 健太郎<br>大阪大学大学院医学系研究科  | 南 陽介<br>国立がん研究センター東病院  | 棟方 理<br>国立がん研究センター中央病院  |
| 10:05 – 10:20 | 15 min | Q&A  |                        |                         |
|               |        | Abstract ID LBA107 / Jason Westin MD, FACP, MS<br>Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.  |                        |                         |
|               |        | Abstract ID 10015 / Ti-Cheng Chang<br>Genomic determinants of outcome in acute lymphoblastic leukemia: A Children's Oncology Group study   |                        |                         |
| 10:20 – 10:40 | 20 min | 棟方 理<br>国立がん研究センター中央病院   | 南 陽介<br>国立がん研究センター東病院  | 福島 健太郎<br>大阪大学大学院医学系研究科 |
| 10:40 – 10:55 | 15 min | Q&A  |                        |                         |
|               |        | Abstract ID LBA4 / Alex Francisco Herrera MD<br>SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).  |                        |                         |
|               |        | Abstract ID 8000 / Stefan Knop MD<br>Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase3 study.   |                        |                         |
| 10:55 – 11:05 | 10 min | Symptoms & Survivorship - 高齢者  |                        |                         |
| 11:05 – 11:15 | 10 min | Q&A  |                        |                         |
|               |        | 水谷 友紀<br>杏林大学医学部   | 片山 英樹<br>岡山大学病院        |                         |
|               |        | Abstract ID 12000 / Cindy Kenis, PhD<br>A multicenter randomized controlled trial (RCT) for the effectiveness of Comprehensive Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study.  |                        |                         |
| 11:15 – 11:25 | 10 min | Symptoms & Survivorship - 心毒性  |                        |                         |
| 11:25 – 11:35 | 10 min | Q&A  |                        |                         |
|               |        | 下村 昭彦<br>国立国際医療研究センター  | 片山 英樹<br>岡山大学病院        | 南 博信<br>神戸大学大学院医学研究科    |
|               |        | Abstract ID 10013 / Saro Armenian, DO, MPH<br>Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621   |                        |                         |
| 11:35 – 11:40 | 5 min  | Break  |                        |                         |
| 11:40 – 12:20 | 40 min | 【座長】 高野 利実（がん研究会有明病院）<br>【演者】 内藤 陽一（国立がん研究センター東病院）   |                        |                         |
| 11:40 – 12:20 | 40 min | オンコロジーライブセミナー⑤ MSD株式会社<br>トリプルネガティブ乳がんの周術期薬物療法   |                        |                         |
| 12:20 – 12:45 | 25 min | Break  |                        |                         |
| 12:45 – 13:15 | 30 min | 泌尿器がん - Nonprostate  |                        |                         |
| 13:15 – 13:30 | 15 min | Q&A  |                        |                         |
|               |        | 前嶋 愛子<br>国立がん研究センター中央病院  | 松原 伸晃<br>国立がん研究センター東病院 |                         |
|               |        | Abstract ID LBA4619* / Yohann Loriot MD, PhD<br>Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo)in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).  |                        |                         |
|               |        | Abstract ID LBA4500 / Toni K. Choueiri MD<br>Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.                                  |                        |                         |
|               |        | Abstract ID LBA4507 / Christian Pfister, MD, PhD<br>Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial. |                        |                         |
| 13:30 – 13:50 | 20 min | 泌尿器がん - Prostate   |                        |                         |
| 13:50 – 14:05 | 15 min | Q&A  |                        |                         |
|               |        | 三浦 徳宣<br>愛媛大学  | 泉 浩二<br>金沢大学附属病院       |                         |
|               |        | Abstract ID 5004 / Karim Fizazi, MD<br>TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.                                       |                        |                         |
|               |        | Abstract ID LBA5000 / Alberto Bossi, MD<br>Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.   |                        |                         |
| 14:05 – 14:10 | 5 min  | Break  |                        |                         |
| 14:10 – 14:30 | 20 min | 頭頸部がん  |                        |                         |
| 14:30 – 14:45 | 15 min | Q&A  |                        |                         |
|               |        | 尾上 琢磨<br>兵庫県立がんセンター  | 岡野 晋<br>国立がん研究センター東病院  |                         |
|               |        | Abstract ID LBA6002 / Jun Ma<br>PD-1 blockade with Sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): a multicenter, phase 3, randomized controlled trial (CONTINUUM)   |                        |                         |
|               |        | Abstract ID 6007 / Ari Rosenberg MD<br>Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.  |                        |                         |
| 14:45 – 15:05 | 20 min | 消化器がん - Hepatobiliary/Pancreas   |                        |                         |
| 15:05 – 15:20 | 15 min | Q&A  |                        |                         |
|               |        | 森實 千種<br>国立がん研究センター中央病院  | 脇岡 範<br>国立がん研究センター中央病院 |                         |
|               |        | Abstract ID 4008 / Shubham Pant MD<br>Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).  |                        |                         |
|               |        | Abstract ID 4006 / Eileen Mary O'Reilly, MD<br>Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.  |                        |                         |
| 15:20 – 15:30 | 10 min | Closing Remarks  |                        |                         |
|               |        | 南 博信<br>神戸大学大学院医学研究科   |                        |                         |

両日ともに統計学専門の先生に  
逐次アドバイザーとしてQ&Aにご参加いただきます

アドバイザー

石塚 直樹  
京都大学

アドバイザー

吉村 健一  
広島大学